Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics
to treat serious and rare diseases, today announced that two
abstracts on lead product candidate luspatercept will be presented
at the 2018 American Society of Clinical Oncology (ASCO) Annual
Meeting held in Chicago, Illinois on June 1-5, 2018. Luspatercept
is being developed as part of a global collaboration between
Acceleron and Celgene.
Poster Presentations at ASCO:
Title:
Erythropoietic Cellular Analyses in
Luspatercept-Treated Lower-Risk Myelodysplastic Syndromes
(MDS): Phase 2 PACE-MDS Study (Abstract: #7018)
Session: Hematologic Malignancies—Leukemia, Myelodysplastic
Syndromes, and Allotransplant Date:
Monday, June 4th
Time: 11:30 a.m. – 12:45 p.m. CDT (McCormick Place, E450)
Title:
A Phase 2, Multicenter, Open-Label
Study of the Safety and Efficacy of Luspatercept inSubjects with
Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis and
Anemia Withor Without RBC Transfusion Dependence (Abstract:
#TPS7083)
Session: Hematologic Malignancies—Leukemia, Myelodysplastic
Syndromes, and Allotransplant Date: Monday, June 4th Time: 8:00
a.m. – 11:30 a.m. CDT (McCormick Place, Hall A)
The MDS Phase 2 poster presentation at the conference will
include updated information beyond that included in the abstract
available on the ASCO conference website on May 16, 2018. The
clinical posters will be available immediately following the
presentations at the conference on June 4, 2018 in the “Science”
section on Acceleron’s website, www.acceleronpharma.com.
About Luspatercept
Luspatercept is a first-in-class erythroid maturation agent
(EMA) that regulates late-stage red blood cell maturation.
Acceleron and Celgene are jointly developing luspatercept as part
of a global collaboration. Phase 3 clinical trials are underway to
evaluate the safety and efficacy of luspatercept in patients with
myelodysplastic syndromes (the MEDALIST trial) and in patients with
beta-thalassemia (the BELIEVE trial). A Phase 3 trial is being
planned in first-line, lower-risk, myelodysplastic syndromes
patients (the COMMANDS trial). The BEYOND Phase 2 trial in
non-transfusion-dependent beta-thalassemia and a Phase 2 trial in
myelofibrosis are ongoing. For more information, please visit
www.clinicaltrials.gov.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical
company dedicated to the discovery, development, and
commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary
program with a Phase 2 trial of sotatercept planned in pulmonary
arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on social media: @AcceleronPharma and
LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements about the
Company's strategy, future plans and prospects, including
statements regarding the development of the Company's compounds,
the timeline for clinical development and regulatory approval of
the Company's compounds and the expected timing for reporting of
data from ongoing clinical trials. The words "anticipate,"
"believe," "could," "estimate," "expect," "goal," "intend," "may,"
"plan," "potential," "project," "should," "target," "will,"
"would," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Actual results could differ materially from those included in
the forward-looking statements due to various risks and
uncertainties, including, but not limited to, that preclinical
testing of the Company's compounds and data from clinical trials
may not be predictive of the results or success of ongoing or later
clinical trials, that the development of the Company's compounds
will take longer and/or cost more than planned, that the Company or
its collaboration partner, Celgene, will be unable to successfully
complete the clinical development of the Company's compounds, that
the Company or Celgene may be delayed in initiating, enrolling or
completing any clinical trials, and that the Company's compounds
will not receive regulatory approval or become commercially
successful products. These and other risks and uncertainties are
identified under the heading "Risk Factors" included in the
Company's most recent Annual Report on Form 10-K, and other filings
that the Company has made and may make with the SEC in the
future.
The forward-looking statements contained in this press release
are based on management's current views, plans, estimates,
assumptions and projections with respect to future events, and the
Company does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180426005278/en/
Acceleron Pharma Inc.Todd James, IRC, (617) 649-9393Vice
President, Investor Relations and Corporate CommunicationsorCandice
Ellis, 617-649-9226Manager, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024